The short answer
Bitter melon may affect glucose control. Review the product before combining it with repaglinide; the exact added low-blood-sugar risk has not been measured.
What this answer covers
Momordica charantia; capsule, fruit and standardized extracts vary.
- Supplement or preparation
- Momordica charantia
- Medication ingredient
- repaglinide
What the human evidence shows
A small type 2 diabetes capsule trial found no significant overall glucose benefit. A separate prediabetes extract study found some post-challenge improvements. Neither established this exact combination’s hypoglycemia risk.
Why your treatment context matters
Repaglinide stimulates insulin release and can cause low blood sugar. The prescriber should consider the full regimen, meals and prior low readings before deciding whether additional monitoring is useful.
Check the supplement preparation
Food portions and concentrated capsules can differ substantially. Bring the species, plant part and extract dose to the pharmacist rather than assuming every bitter melon preparation has the same effect.
Keep the prescribed medicine plan
Take repaglinide within thirty minutes before meals as prescribed and skip its dose when a meal is skipped. Review supplement changes with the prescriber instead of inventing a separation interval or adjusting the medicine yourself.
Watch for low blood sugar
Follow your existing glucose-monitoring and low-blood-sugar treatment plan. New sweating, shakiness, hunger or confusion warrants a glucose check when possible. Severe confusion, a seizure or inability to swallow safely needs emergency help.
Evidence and practical considerations
Side effects & toxicity
Conditional glucose-monitoring concern follows from supplement glucose effects and the exact medicine context. This is not direct evidence of increased hypoglycemia or altered drug absorption.
- Exact scope
- Momordica charantia; capsule, fruit and standardized extracts vary. with Exact repaglinide oral tablets. Exact RxNorm IN73044 oral repaglinide; CYP2C8, CYP3A4 and transporters must not be equated with nateglinide pathways.
- Medication form and route
- oral
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- No exact pair human interaction trial identified. Preparation-specific positive and null results do not establish a universal effect, safe dose, spacing rule or drug concentration change.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed repaglinide.
Insulin secretagogue with hypoglycemia risk; within thirty minutes before meals and skip dose with skipped meal; nicotinic acid may reduce glucose-lowering effect, salicylates may increase it.
How this applies: Exact RxNorm IN73044 oral repaglinide; CYP2C8, CYP3A4 and transporters must not be equated with nateglinide pathways.
No universal supplement dose, interval, event rate or untested formulation equivalence.
Source 2: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 40 adults with type 2 diabetes on standard treatment.
No significant benefit in HbA1c, fasting glucose or several other metabolic outcomes; a few mild adverse events occurred.
How this applies: Only the original species, preparation, population and measured endpoint apply. No exact-pair clinical rate inferred.
Small trial; original abstract does not identify repaglinide co-use. Product findings are not proof about every preparation.
Source 3: Original human clinical study
pmc.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 76 participants with prediabetes randomized; glucose-affecting medicines excluded.
Some post-challenge glucose and glucagon measures improved.
How this applies: Only the original species, preparation, population and measured endpoint apply. No exact-pair clinical rate inferred.
Selected untreated population, product-specific findings and multiple glucose measures. This was not a repaglinide combination trial.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. |
Article revision: bc37c8b033097726
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.